ID: ALA3706464
Max Phase: Preclinical
Molecular Formula: C21H20N2O5
Molecular Weight: 380.40
Molecule Type: Small molecule
Associated Items:
ID: ALA3706464
Max Phase: Preclinical
Molecular Formula: C21H20N2O5
Molecular Weight: 380.40
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1cc(CO)nc(O[C@H](C(=O)O)C(O)(c2ccccc2)c2ccccc2)n1
Standard InChI: InChI=1S/C21H20N2O5/c1-14-12-17(13-24)23-20(22-14)28-18(19(25)26)21(27,15-8-4-2-5-9-15)16-10-6-3-7-11-16/h2-12,18,24,27H,13H2,1H3,(H,25,26)/t18-/m1/s1
Standard InChI Key: YBIPKWXGCZRQDQ-GOSISDBHSA-N
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 380.40 | Molecular Weight (Monoisotopic): 380.1372 | AlogP: 2.05 | #Rotatable Bonds: 7 |
Polar Surface Area: 112.77 | Molecular Species: ACID | HBA: 6 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 3.42 | CX Basic pKa: 2.30 | CX LogP: 2.03 | CX LogD: -1.11 |
Aromatic Rings: 3 | Heavy Atoms: 28 | QED Weighted: 0.57 | Np Likeness Score: -0.11 |
1. FDA drug approval package for Ambrisentan, |
Source(1):